82 related articles for article (PubMed ID: 23987046)
21. Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.
Elhilali M; Emberton M; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Alcaraz A; Vallancien G;
BJU Int; 2006 Mar; 97(3):513-9. PubMed ID: 16469018
[TBL] [Abstract][Full Text] [Related]
22. [The efficacy of alfuzosin (dalfaz) in patients with benign prostatic hyperplasia].
Tkachuk VN; Kuz'min IV
Urol Nefrol (Mosk); 1998; (2):38-40. PubMed ID: 9577703
[TBL] [Abstract][Full Text] [Related]
23. [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
Mazo EB; Matushevskiĭ IA; Nikitin IuIu
Ter Arkh; 1997; 69(10):79-82. PubMed ID: 9471799
[TBL] [Abstract][Full Text] [Related]
24. [Clinical effectiveness and safety study of combined therapy with an alpha-blocker and an anticholinergic for patients with LUT/BPH].
Xiao H; Li HZ; Yang Y; Huang ZM; Li YQ; Zhao XF
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(23):1590-3. PubMed ID: 17803845
[TBL] [Abstract][Full Text] [Related]
25. Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily.
Hartung R; Matzkin H; Alcaraz A; Emberton M; Harving N; van Moorselaar J; Elhilali M; Vallancien G;
J Urol; 2006 Feb; 175(2):624-8; discussion 628. PubMed ID: 16407011
[TBL] [Abstract][Full Text] [Related]
26. Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patient's quality of life. The Italian Alfuzosin Cooperative Group.
Eur Urol; 1995; 27(2):128-34. PubMed ID: 7538083
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study.
Lee JY; Cho SY; Oh CY; Ha US; Lee SH; Park SY; Moon HS; Lee SW
Int J Impot Res; 2011; 23(6):249-56. PubMed ID: 21814227
[TBL] [Abstract][Full Text] [Related]
28. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
[TBL] [Abstract][Full Text] [Related]
29. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy of an alpha-blocker, alfuzosin, on urinary disorders in men with prostatic adenoma. Intermediate results of a European multicenter study].
Jardin A
Ann Urol (Paris); 1988; 22(5):333-40. PubMed ID: 2462402
[TBL] [Abstract][Full Text] [Related]
31. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.
Broderick GA; Brock GB; Roehrborn CG; Watts SD; Elion-Mboussa A; Viktrup L
Urology; 2010 Jun; 75(6):1452-8. PubMed ID: 20163842
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of orally disintegrating tamsulosin tablets in Taiwanese patients with benign prostatic hyperplasia.
Lin KH; Lin YW; Wen YC; Lee LM
Aging Male; 2012 Dec; 15(4):246-52. PubMed ID: 23067262
[TBL] [Abstract][Full Text] [Related]
33. [Clinical effects of beta-sitosterol (phytosterol) on benign prostatic hyperplasia: preliminary study].
Kobayashi Y; Sugaya Y; Tokue A
Hinyokika Kiyo; 1998 Dec; 44(12):865-8. PubMed ID: 10028431
[TBL] [Abstract][Full Text] [Related]
34. [A multicenter, fixed-flexible dose study of terazosin hydrochloride in the treatment of symptomatic benign prostatic hypertrophy].
Park YC; Nishioka T; Arai Y; Tomoyoshi T; Kurita T; Hayashida H; Nagai N; Inoue H; Kataoka K; Kitagawa Y
Hinyokika Kiyo; 1992 Jul; 38(7):857-68. PubMed ID: 1381869
[TBL] [Abstract][Full Text] [Related]
35. [A clinical trial of the treatment of patients with benign prostatic hyperplasia using the alpha 1-adrenoblocker alfuzosin].
Lopatkin NA; Perepanova TS
Urol Nefrol (Mosk); 1997; (5):14-6. PubMed ID: 9412005
[TBL] [Abstract][Full Text] [Related]
36. [Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia].
Sugino Y; Fukuzawa S; Takeuchi H; Taki Y; Hashimura T; Soeda T; Araki I
Hinyokika Kiyo; 2003 Aug; 49(8):445-9. PubMed ID: 14518379
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Kongkanand A; Chodchoy V; Lojanapiwat B; Pumpaisanchai S; Ratana-Olarn K; Sae-Tang P; Taweemonkongsap T
J Med Assoc Thai; 2009 Jul; 92(7):969-78. PubMed ID: 19626818
[TBL] [Abstract][Full Text] [Related]
38. Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan.
Tsai YS; Lan SK; Ou JH; Tzai TS
Clin Ther; 2007 Apr; 29(4):670-82. PubMed ID: 17617290
[TBL] [Abstract][Full Text] [Related]
39. Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report.
Palacio A; Hernández C; Marqués A; Prats J; Espinosa FJ
Arch Esp Urol; 2004 May; 57(4):451-60. PubMed ID: 15270291
[TBL] [Abstract][Full Text] [Related]
40. Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial.
Goldfischer E; Kowalczyk JJ; Clark WR; Brady E; Shane MA; Dgetluck N; Klise SR
Urology; 2012 Apr; 79(4):875-82. PubMed ID: 22341603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
